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The presence of the calcium-independent cytokine-inducible
nitric oxide synthase (iNOS) has been investigated in rat placenta
from day 19 of gestation till delivery. iNOS has been detected at
the mRNA, enzyme activity and protein levels in complete
placenta. Immunocytochemical detection of iNOS was hetero-
geneously distributed in control placenta. Intraperitoneal in-
jection of pregnant rats at 21 days of gestation with lipopoly-
INTRODUCTION
Nitric oxide (NO) is a messenger molecule playing key roles in
multiple physiological processes [1]. Synthesis of NO from l-
arginine is catalysed by NO synthase (NOS; EC 1.14.13.39). At
least three different NOS isoenzymes have been identified in
mammalian tissues, exhibiting an important degree of tissue-
specific expression as well as major differences in their regulatory
properties [1–3]. Two constitutively expressed Ca#+}calmodulin
dependent NOS isoforms are mainly present in brain (nNOS)
and endothelia (eNOS), and share 60% homology at the amino
acid sequence level. A third form, cytokine-inducible Ca#+-
independent NOS (iNOS), is expressed in cells such as macro-
phages, neutrophils and hepatocytes, after stimulation with
lipopolysaccharide (LPS) and pro-inflammatory cytokines. Three
distinct cDNAs encoding neuronal [4], endothelial [5,6] and
macrophage forms of NOS [7–9] have been isolated.
It has been suggested that increased NO production plays a
role in the haemodynamic accommodation characteristic of
pregnancy [10]. Increased NO biosynthesis has been detected in
both pregnant rats and humans [10,11]. During pregnancy NOS
activity is expressed in the placental villous tree where it may act
to regulate placental blood flow, fetal nutrition and growth. This
NOS activity correlates with plasma progesterone levels in the
uterus and decidua preterm [11,12]. Chronic reduction in NO
production in rats during the last third of pregnancy resulted in
significant intrauterine growth retardation and haemorrhagic
foci in fetal hind limbs [13].
The NOS isoenzymes present in the placenta responsible for
continuous NO synthesis have been characterized using various
complementary approaches, including measurement of the en-
zyme activity [11], the use of more or less specific NOS inhibitors
[10,13] and immunohistochemistry [10,11]. Most of the research
in this field has focused on the distribution and activity of the
eNOS isoenzyme [11]. However, the presence of an important
Ca#+-independent NOS activity has been reported [14,15].
The placenta has a number of important functions during
pregnancy, both biological and immunological. As expected
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saccharide (LPS) increased the iNOS immunoreactivity in the
decidua basalis of the placenta, and, when the mRNA levels and
enzyme activity were measured in total tissue, a moderate increase
(approx. 160%) was observed. A constitutive nuclear factor jB
activity was observed in placenta from both control and LPS-
treated animals. These results indicate constitutive expression of
iNOS in rat placenta.
from the anatomical structure, the presence of constitutive eNOS
in human placental villous tissue, endothelium of the umbilical
artery and vein, and the trophoblast has been reported [15–17] ;
however, few data are available describing the presence and
function of the iNOS in placental tissue.
The present study was undertaken to investigate the presence
of iNOS in complete placenta from pregnant rats and to compare
the abundance of this isoenzyme with respect to eNOS. Our
results show that iNOS is significantly expressed in the placenta
and the possible mechanisms supporting the expression of this
isoform are discussed.
MATERIAL AND METHODS
Chemicals
[a-$#P]Deoxycytidine triphosphate (3000 Ci}mmol) and [U-
"%C]arginine (292 mCi}mmol) were from Amersham Inter-
national (Little Chalfont, Bucks., U.K.). Restriction enzymes
were from Boehringer (Mannheim, Germany). Other chemicals
and biochemicals were from Sigma (St. Louis, MO, U.S.A.) and
Merck (Darmstadt, Germany). Chemicals for electrophoresis
were from Bio-Rad (Richmond, CA, U.S.A.). LPS was from
Salmonella typhimurium (Sigma).
Animals and preparation of cells
Pregnant albino Wistar rats (300–350 g), fed ad libitum on a
standard laboratory diet, were used. Pregnancy and gestational
age were determined by standard criteria [18], and the animals
were killed between 08:30–09:30 h. Placenta were removed by
Caesarean section after Nembutal anaesthesia of the dam. Except
where stated, the complete placenta without the umbilical vein
was used in the preparation of the samples used. The placenta
was quickly freeze-clamped in liquid N
#
.
Samples for immunohistochemistry were collected as follows:
deeply anaesthetized animals (intraperitoneal injection of
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2.5 ml}kg body weight of Equithesin; Janssen Laboratories)
were ventilated through a tracheal cannula and perfused through
the left ventricle with 50 ml of 0.9% saline as a vascular rinse,
followed by 500 ml of fixative solution (4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4). The placenta was removed, cut
into 4–5 mm coronal blocks, and post-fixed for 4 h with fixative
solution. LPS was injected intraperitoneally at 1 mg}kg body
weight for the indicated period of time.
Resident peritoneal macrophages were prepared from rats
lightly anaesthetized with ether as described [19]. Rat endothelial
cell cultures were prepared as described previously [20]. Animal
care was as indicated in the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health, U.S.A. (N.I.H. 80-23).
iNOS enzyme activity assay
Placenta from control or LPS-treated pregnant rats were homo-
genized in 4 vol. (w}v) of a medium containing 20 mM Tris}HCl
(pH 8), 1 mM dithioerythritol (DTE), 10 lM 6R-5,6,7,8-
tetrahydro-l-biopterin (Dr. B. Schirck’s Laboratories, Jona,
Switzerland), 10 lM leupeptin and 0.5 mM PMSF. The homo-
genate was centrifuged at 105000 g for 30 min and the super-
natant was subjected to 2«,5«-ADP–Sepharose chromatography
to partially purify NOS [19,21]. NOS activity was followed by the
production of [U-"%C]citrulline from [U-"%C]arginine [21]. The
reaction mixture contained 50 lM [U-"%C]arginine (0.3 lCi),
20 mMHepes (pH 7.5), 1 mM EGTA, 0.5 mM NADPH, 0.1 mM
DTE and 10 lM 6R-5,6,7,8-tetrahydro-l-biopterin (200 ll final
volume). After incubation for 10 min at 30 °C, an ice-cold
solution of 10 mM EGTA}0.1 mM citrulline}10 mM Pipes,
pH 5.5 (1 ml) was added and 1 ml of this mixture was applied to
a Dowex AG 50W-X8 (Na+ form) column (1 ml vol.). [U-"%C]-
Citrulline was eluted with water (3 ml) and the radioactivity in
the eluate was estimated by scintillation spectroscopy. The
enzyme activity was expressed as the difference in product
formation in the absence or presence of 0.25 mM N-methyl-l-
arginine in the reaction mixture [22].
Western blot analysis of iNOS and eNOS
Placenta, cultured resident peritoneal macrophages from control
or LPS-treated rats and cultures of rat vascular endothelial cells
were each homogenized in a medium containing 20 mM Tris}HCl
(pH 7.4), 1 mM EDTA, 10 mM b-mercaptoethanol, 200 mM
NaCl, 2 lg}ml leupeptin, 50 lg}ml tosyl-lysylchloromethane,
100 lg}ml PMSF and 0.5% (v}v) Triton X-100 at 4 °C. After
centrifugation at 105000 g for 30 min, the protein content of
each supernatant was determined and 1 ml portions, containing
the same amount of protein, were each mixed with 100 ll of an
ADP–Sepharose 4B suspension [1:1 (w}v) in the same medium].
After thorough mixing for 30 min at 4 °C, the ADP–Sepharose
gel was washed ¬3 with 1 ml of PBS and the gel suspension was
centrifuged in an Eppendorf centrifuge for 15 min. The pellets
were boiled in Laemmli sample buffer [250 mM Tris}HCl
(pH 6.8), 2% (w}v) SDS, 10% (v}v) glycerol and 2% b-
mercaptoethanol] (150 ll), and proteins were separated by
SDS}PAGE (10% gels) [23]. The proteins were transferred to
poly(vinylidine difluoride) membranes (Millipore) (3 mA}cm#
for 4 h), hybridized with either the anti-murine iNOS antibody
(Ab), as recommended by the supplier (Transduction Lab-
oratories), or with the anti-bovine eNOS Ab (generously given by
Dr. S. Lamas, Centro de Investigaciones Biologicas, Madrid),
and detection was achieved using enhanced chemiluminescence
(Amersham International). The iNOS Ab (used at 1:2500
dilution) recognized a common band in extracts from mouse and
rat peritoneal macrophages, which had been stimulated for 24 h
with 1 lg}ml of LPS, but not in the corresponding unstimulated
cells. The eNOS Ab (used at 1:1000 dilution) recognized a
140 kDa band in both bovine and rat cultured endothelial cells,
but not in mouse or rat macrophages.
Northern blot analysis
Total RNA was extracted by the guanidinium isothiocyanate
method and aliquots of RNA (30 lg) were separated by electro-
phoresis in a 0.9% (w}v) agarose gel containing 2% (v}v)
formaldehyde (20 mA for 15 h) [24]. The RNA was transferred
to a Nytran membrane (NY 13-N; Schleicher & Schuell, Dassel,
Germany) using 10¬SSC (1.5 M NaCl}0.3 M sodium citrate,
pH 7.4) The membrane was prehybridized and the levels of iNOS
and eNOS mRNA were determined using EcoRI-HindII and
EcoRI fragments from the iNOS (murine) and eNOS (bovine)
cDNAs, respectively [5,7], labelled with [a-$#P]dCTP using the
Rediprime labelling kit (Amersham International) as probes.
The membranes were washed with 0.1¬SSC and 0.1% (w}v)
SDS at room temperature for 10 min and twice at 50 °C for
30 min, before being exposed to X-ray film (Hyperfilm).
Quantification of the NOS mRNA was performed by laser
densitometry (Molecular Dynamics) using, as a control, a probe
specific for 18 S rRNA inserted into a PBR322 plasmid. The
specificity of the probes was assessed by comparing the hybridiza-
tion of LPS-activated murine macrophages (iNOS) and bovine
endothelial cells (eNOS) [5,19].
Preparation of nuclear extracts
A modified procedure based on the method of Costa et al. was
used [25]. Placenta from control or LPS-treated rats were
homogenized in 8 vol. (w}v) of buffer A [10 mM Hepes (pH 7.9),
1 mM EDTA, 1 mM EGTA, 10 mM KCl, 1 mM DTE, 0.5 mM
PMSF, 2 lg}ml aprotinin, 10 lg}ml leupeptin, 2 lg}ml tosyl-
lysylchloromethane, 5 mM NaF, 1 mM NaVO
%
, 10 mM
Na
#
MO
%
, 0.15 mM spermine, 0.5 mM spermidine, 0.5 M sucrose,
50 lg}ml trypsin inhibitor]. After incubation for 10 min at 4 °C,
Nonidet P-40 was added [0.5% (v}v) final concentration]. The
tubes were vortexed gently for 15 s and the nuclei were sedimented
by centrifugation at 800 g for 15 min at 4 °C. The supernatants
were stored at ®80 °C (cytosolic extract) ; the nuclei pellets were
resuspended in 250 ll of buffer A supplemented with 20% (v}v)
glycerol and 0.4 M KCl and incubated for 30 min with gentle
vortexing. Nuclear proteins were separated by centrifugation at
13000 g for 15 min and aliquots of the supernatant were stored
at ®80 °C. Proteins were measured using the Bio-Rad
(Richmond, CA, U.S.A.) protein reagent [26]. All steps of cell
fractionation were carried out at 4 °C.
Electrophoretic mobility shift assay (EMSA)
Synthetic oligonucleotides corresponding to the proximal jB
motif of the iNOS promoter were prepared using a Pharmacia
oligonucleotide synthesizer [27,28]. The oligonucleotide (5«-
CCAACTGGGGACTCTCCCTTTGGGAACA-3«) was an-
nealed after incubation for 5 min at 85 °C in 10 mM Tris}HCl
(pH 8), 50 mM NaCl, 10 mM MgCl
#
and 1 mM DTE. Aliquots
of 100 ng of annealed oligonucleotides were end-labelled with
Klenow enzyme fragment in the presence of 50 lCi of [a-
$#P]dCTP and the other unlabelled dNTPs in a final volume of
20 ll. The oligonucleotides were precipitated with ethanol and
extracted with phenol}chloroform (1:1). The DNA probe (10&
d.p.m.) was used for each binding assay as follows: 8 lg of
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protein extract were incubated for 15 min at 4 °C with the DNA
and 2 lg}ml of poly(dI :dC), 5% glycerol, 1 mMEDTA, 100 mM
KCl, 5 mM MgCl
#
, 1 mM DTE and 10 mM Tris}HCl, pH 7.8, in
a final volume of 15 ll. The incubation mixture was applied to a
6% (w}v) polyacrylamide gel which had been electrophoresed
previously for 30 min at 100 V. The gels were run at 0.8 V}cm#
in 45 mM Tris}borate, pH 8.0, transferred to 3MM Whatman
paper, dried under vacuum at 80 °C and exposed to X-ray film.
RNase protection assay
An antisense riboprobe was generated using T7 RNA polymerase
after subcloning a fragment of 450 bp in a pGEM5ZF vector
(Promega) and linearization with HindIII [7]. The cRNA
contained 450 bp and was complementary to bases 161–614 of
the murine iNOS mRNA. Total RNA (5 lg) from macrophages,
macrophages treatedwith LPSor placenta (30 lg) were incubated
at 85 °C for 5 min with a molar excess (800000 counts}min) of
the riboprobe and hybridized at 45 °C overnight. A mixture of
RNase T (2 lg}ml) and RNase A (40 lg}ml) was used to
degrade the single-stranded unhybridized probe for 1 h at 30 °C,
and the digested products were analysed on a 6% (w}v)
acrylamide}8 M urea gel. The gel was dried and auto-
radiographed.
Immunohistochemistry
Fixed placenta from control and LPS-treated animals were
frozen and serial 40-lm-thick frontal sections were cut with a
Leitz sledge microtome. Free-floating sections were incubated
with iNOS affinity-purified polyclonal antiserum (Transduction
Laboratories). The sections were processed by the avidin–biotin
peroxidase complex (ABC) procedure [29,30] to visualize
immunoreactive sites. Control procedures were carried out in
two animals, and no immunolabelling was observed when the
primary antibody was omitted or replaced with an equivalent
concentration of preimmune and normal rabbit serum.
Data analysis
All experiments were carried out by assaying the samples in
duplicate or triplicate. Statistical analyses were performed by the
Student’s t test for paired data (parametric test) and by the
Wilcoxon test (non-parametric values). P! 0.05 was considered
significant.
RESULTS
Presence of iNOS in placental tissue
Total RNA was extracted from complete placenta of rats at day
20 and 21 of gestation and was hybridized with iNOS and eNOS
probes. As shown in Figure 1(A), the placental tissue exhibited
a band (4.4 kb) with the iNOS probe, whereas in cultured rat
vascular endothelial cells the levels of iNOS mRNA were
undetectable. In a positive control, an intense band of iNOS was
observed in mRNA samples from peritoneal rat macrophages
treated with LPS. The same samples were used to determine the
amount of eNOS and only rat endothelial cells exhibited an
intense band when hybridized with the corresponding eNOS
probe. However, overexposure of the film revealed, as expected
from results from other groups [11], a faint band in placenta but
not in macrophages (results not shown). These data suggest that
in complete placenta the iNOS mRNA is more abundant than
that of the eNOS isoenzyme. This was also observed at the
protein level where the amount of immunoreactive iNOS
Figure 1 mRNA and protein levels of iNOS and eNOS in placenta
Total RNA and protein extracts were prepared from complete placenta on days 20 or 21 of
gestation, as indicated. Rat peritoneal macrophages (Mu) were cultured for 18 h in the absence
or presence of 0.5 lg/ml of LPS. Rat vascular endothelial cells were cultured until confluent.
(A) Total RNA (30 lg) from each preparation was used to determine the content of iNOS and
eNOS mRNA by Northern-blot analysis. Normalization of lane charge was carried out by
hybridization with an 18 S ribosomal probe. (B) Protein (10 lg) from each preparation was
used to determine the iNOS and eNOS protein content by Western-blot analysis. The results
shown are representative of four experiments.
correlated with the corresponding mRNA levels (Figure 1B).
Moreover, when an eNOS specific antibody was used, the amount
of protein detected in extracts from complete placenta was very
low when compared with the relative abundance in the cultured
rat endothelial cells.
Despite the correlation between the mRNA and protein levels
of iNOS it was important to establish that the mRNA detected
in placenta with the iNOS probe effectively corresponded to this
isoenzyme. To do this, RNA from LPS-stimulated placenta and
macrophages, which produced a similar band in Northern blot
when hybridized with the iNOS probe, were analysed by the
RNase protection assay. As shown in Figure 2, the pattern of
bands in samples from LPS-treated macrophages and placenta
was identical with two important protected bands of 116 and
111 bp which confirms the presence of iNOS mRNA in the total
tissue. The presence of several bands in the gel was due to the use
of a mouse riboprobe with minimal differences in the sequence
with respect to the rat counterpart.
The relative amount of iNOS mRNA in placenta was studied
using animals at different gestational ages. As shown in Figure 3,
no significant differences in iNOS levels were observed between
day 19 of gestation and delivery. Because pregnant animals
suffering septic shock are more likely to abort or suffer other
materno}fetal dysfunctions [31] we investigated whether the
placental iNOS mRNA levels could be up-regulated in animals
with this condition. Treatment of rats of 21 days of gestation
with LPS moderately increased (164%) the amount of placental
iNOS mRNA (Figure 3), whereas in other maternal tissues (liver
and peritoneal macrophages) a large increase in iNOS mRNA
was observed (results not shown).
Because the anatomy of the placenta includes various cell
types, fixed tissue sections were analysed for the immuno-
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Figure 2 RNase protection assay of iNOS
RNA (5 lg) from primary cultures of rat macrophages (Mu) was incubated for 18 h in the
absence or presence of 0.5 lg/ml of LPS, or placental RNA (30 lg) from rats at 21 days of
gestation was incubated with a riboprobe from the murine iNOS gene. After RNase treatment
the samples were analysed by PAGE. DNA from phage NX174 digested with HindI was used
as a size marker for the bands. The results shown are representative of three experiments.
localization of iNOS. In control placenta, immunoreactive cells
were found heterogeneously distributed throughout the placental
villi and specifically near and under the chorionic plate. The
cotyledons and villi were non-immunoreactive (Figure 4A).
Magnification of the section showed that each villus is covered
by a thin layer of syncytio-trophoblasts containing fetal
capillaries, mesoderm and multipolar syncytial immunoreactive
cells (Figure 4B). A detail of syncytial cells shows the granular
nature of the immunoreactive end-product (Figure 4C), similar
to that described previously in activated macrophages [32].
Placenta from LPS-treated animals (Figure 5A) showed increased
immunoreactivity distributed near the basal plate or maternal
septum, decidua basalis and in the periphery of the cotyledons.
The reaction product in the immunoreactive cells appeared as
immunopositive cytoplasmic granules surrounding clear and
large nuclei (Figures 5B and 5C).
NOS activity in placenta
NOS activity was measured in samples of complete placenta
following the synthesis of [U-"%C]citrulline from [U-"%C]arginine
[21]. As shown in Table 1, no statistically significant differences
in NOS activity were observed in placenta from day 19 to 22 of
gestation. When the placenta from animals of 21 days of gestation
Figure 3 Presence of iNOS mRNA in complete placenta
Total RNA (30 lg) from placenta was analysed by Northern blot using a probe specific for iNOS.
Placenta from animals at 21 days of gestation injected intraperitoneally with LPS were also
analysed. The results show the means³S.E.M. of three experiments in which a pool of three
placentae from different animals was used. *, P ! 0.005.
treated with LPS was assayed, a 162% increase of NOS activity
was observed after 8 h of treatment.
Nuclear extracts from placenta contain proteins involved in iNOS
expression
Since iNOS expression is mainly controlled at the transcriptional
level, nuclear factors involved in the transcription of this gene
would be expected to be active in placenta. The expression of
iNOS has been associated with persistent nuclear factor (NF)-jB
activation as a necessary requirement [27,28]. To address this
point we investigated, using the EMSA, whether the sequence
corresponding to the proximal NF-jB motif of the mouse iNOS
promoter region binds members of the NF-jB family. As Figure
6 shows, nuclear proteins prepared from total placental extracts
(day 19 to 22 of gestation) specifically bind to the proximal
NFjB sequence of iNOS in the EMSA. Analysis of the proteins
by supershift assays and by Western blot using specific antibodies
revealed that these bands corresponded to p50–p50 homodimers
and to p50–p65 heterodimers respectively (results not shown).
When placental samples from animals treated with LPS were
analysed, a 5-fold increase in the p50–p65 heterodimers was
observed.
DISCUSSION
Flow of nutrients from the maternal circulation towards the fetus
constitutes an essential requisite for fetal growth. This process is
mediated by the flux of precursors through the placental barrier
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Figure 4 Immunochemical detection of iNOS in rat placenta
Distribution of iNOS immunoreactivity in placenta from rats at 21 days of gestation. (A) Cross-
section of a control placenta. (B) Magnification of the placental villi. (C) Detail of immunoreactive
syncytial cells. The arrows indicate the distribution of immunoreactive sites. Abbreviations : ch,
chorionic plate ; st, stem of villus ; uv, umbilical vein ; ivp, intervilli space ; sy, syncytio-
trophoblast ; M, myometrium ; ps, placental septum ; sb, spiral blood vessel ; db, decidua basalis.
Bars correspond to 0.01 mm.
Figure 5 Detailed iNOS immunoreactivity in placenta from LPS-treated
rats
Pregnant rats at 21 days of gestation were treated with LPS for 8 h. (A) Cross-section of
placenta from LPS-treated rats. (B) Immunoreactivity of syncytial cells (sy). (C) High-power
magnification of (B). Abbreviations : ch, chorionic plate ; uv, umbilical vein ; sy, syncytio-
trophoblast ; ps, placental septum ; sb, spiral blood vessel ; db, decidua basalis. Bars correspond
to 0.01 mm. Arrows indicate immunoreactivity.
and umbilical vein [33], and therefore regulation of blood flow
is an essential component of fetal development.One characteristic
of both umbilical and placental circulation is the absence of
innervation, and, for this reason, it is conceivable that the
existence of multiple alternative mechanisms may be involved in
the regulation of the vascular tone [34]. In support of this, the
presence of eNOS as well as the effective synthesis of NO by
endothelial cells in the umbilical vessels has been established [35].
Some controversy exists regarding the nature of the NOS activity
present in endothelial cells of umbilical vessels ; in addition to
eNOS, some authors claim the presence of nNOS at the end of
pregnancy [36], as well as a calcium-independent NOS activity,
Table 1 NOS activity in placenta
NOS activity was measured in extracts of complete placenta after partial purification by 2«,5«-
ADP–Sepharose on various days of gestation. Where pregnant rats (21 days of gestation) were
injected intraperitoneally with LPS, NOS activity was measured at the indicated times after
treatment. The results are the means³S.E.M. of four experiments in which a pool of four
placenta was used. *, P ! 0.01, LPS-treated versus control placenta.
Days of
gestation
LPS
treatment
(h)
NOS activity
(units per mg
of protein)
19 – 27.4³2.0
20 – 26.6³2.1
21 – 30.2³2.6
22 – 26.6³2.8
21 0 28.1³2.5
21 2 29.5³2.7
21 4 38.7³2.7
21 8 45.0³3.2*
p50–p65
p50–p50
Figure 6 Binding of nuclear proteins to the jB motif of the promoter region
of iNOS
Nuclei were isolated from complete placenta from either control or from LPS-treated rats after
1 h of treatment, on the indicated days of gestation. Nuclear protein extracts were prepared as
described in the Materials and methods section and were incubated with an oligonucleotide
sequence corresponding to the proximal jB motif of the murine promoter region of iNOS. After
PAGE, the ratio between the intensity of the bands corresponding to the p50–p65 heterodimers
and the p50–p50 homodimers was measured. The results shown are the mean intensity ratio
(³S.E.M.) of three experiments. *, P ! 0.01.
which presumably corresponds to iNOS [15,37,38]. Moreover,
the physiological role of placental NO synthesis has been related
to the mechanism responsible for the vasodilation present in
pregnancy and impairment of NO synthesis is a likely candidate
for pregnancy-induced hypertension, a common cause of ma-
ternal and fetal morbidity and mortality [39]. Indeed, the presence
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of iNOS activity has been identified in human placenta in
pathological conditions such as diabetes [38].
Several reports show an important increase in NO synthesis
during pregnancy both in human and in rat [10–12]. This
increased NO synthesis has been detected using various
approaches : (1) an enhanced release of urinary nitrates, even in
animals fed a low nitrate diet ; (2) a reduction in the secretion of
nitrate after administration of different NOS inhibitors, and (3)
the detection of complexed NO haemoglobin by paramagnetic
resonance spectroscopy in the blood of pregnant animals [10,11].
The synthesis of NO may involve the activity of various NOS
isoenzymes, since a variety of more or less selective inhibitors of
NOS isoforms all affect fetal development. This has been shown
for aminoguanidine, a preferred inhibitor of iNOS, which when
given to pregnant rats induces serious alterations in fetal de-
velopment [40]. Several histochemical studies have shown the
presence of NOS activity, mostly eNOS and to a lesser extent
nNOS, in various structures of the placenta [11,35,36]. Our data
showing an significant amount of iNOS mRNA and protein in
total rat placenta fromhealthy animalswas unexpected, especially
when compared with the moderately low levels of eNOS detected
using the same approaches. The samples analysed were from day
19 of gestation to delivery, a period in which the role of NO
synthesis seems to be particularly critical [36,39]. Due to the large
amount of iNOS mRNA measured, and because this result was
contrary to our expectation, appropriate controls were carried
out to ensure that the iNOS isoform was effectively expressed in
placenta. (1) The iNOS and eNOS probes used for Northern-blot
analysis specifically recognized the iNOS and eNOS mRNA in
various control tissues (the same blot was used for Northern-blot
hybridizations shown in Figure 1). (2) RNase protection analysis
of the iNOS from placenta and rat macrophages stimulated with
LPS yielded the same band profile when the mouse iNOS probe
was used, confirming the presence of iNOS. Moreover, an absence
of bands was observed when RNA from endothelial cells was
used (results not shown). (3) A polyclonal antibody raised against
iNOS recognized the protein in the placenta, but not in en-
dothelial cells or unstimulated macrophages. (4) An high level of
calcium-independent activity was measured in extracts from
complete placenta. Altogether, these data support the presence
of iNOS in placenta under physiological conditions.
Because septic shock is an unfavourable condition during
pregnancy [13,31], the possibility of an enhanced iNOS expression
in the placenta of rats suffering septic shock was investigated.
Our results indicate that the total amount of iNOS mRNA
increased moderately under these conditions. At the protein
level, a roughly parallel increase in the enzymic activity was
observed. However, immunocytochemical localization revealed
preferential accumulation in the maternal villi, with only a
minimal expression in the fetal region. Moreover, a certain cell-
specificity was observed in the expression of iNOS in response to
LPS. These results suggest an important role for placenta in
protection against the up-regulation of iNOS in fetal tissue. The
cytokines released in the course of septic shock may exert a more
pronounced effect in the fetus than NO itself. This is the case for
tumour necrosis factor-a, which specifically impairs fetal growth
[31,41]. Also, it is possible that, in the course of LPS treatment,
down-regulation of eNOS occurs as reported previously [1,2].
The activity of iNOS is mainly controlled at the transcriptional
level [2,3]. This is because this isoenzyme, unlike the eNOS and
nNOS isoenzymes, is not regulated by effectors such as calcium}
calmodulin [3]. Therefore, the amount of iNOS protein correlates
closely to the activity of this enzyme. Studies on the mechanisms
that regulate iNOS expression in rodent cells revealed that
activation of the NF-jB transcription factor is a necessary but
not sufficient requirement for the transactivation of the gene
[7–9,27,28]. NF-jB activity is retained in the cytosol through
interaction with an inhibitory subunit such as inhibitory-jB;
degradation of inhibitory-jB favours the translocation of NF-jB
to the nucleus and the binding of NF-jB to regulatory sequences
[42]. When NF-jB activation was measured in nuclear extracts
from placenta, specific binding to the jB motif of the iNOS
promoter was observed and the presence of p50 homodimers and
p50–p65 heterodimers was apparent. Although the cells con-
taining activated NF-jB remain uncharacterized, the relative
abundance of active NF-jB complexes in nuclei from placental
cells supports the possibility of continuous transcription of iNOS
in some cell types. Indeed, when pregnant animals were injected
with LPS, an increase in NF-jB was apparent concomitant with
a moderate increase in the mRNA levels of iNOS. Taking these
results together, we can hypothesize that the cells expressing
iNOS under physiological conditions probably reflect the ex-
istence of a constitutive or autocrine activation mechanism. One
likely candidate is relaxin, which is produced in the uterus and
has been described as an inducer of iNOS at the end of pregnancy
[43]. However, further work is required to determine more
precisely the nature of the cells responsible and the mechanism of
triggering iNOS expression in the placenta.
Finally, the presence of physiological and constitutively
expressed iNOS in the course of development is not only restricted
to the placenta. The physiological presence of iNOS in fetal brain
vessels replaced by eNOS in the course of development has been
demonstrated recently [44]. Unravelling of whether the results
observed in rat placenta parallel the situation in the human
counterpart merits further research.
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